Pioneering therapies for people with neurological disorders
News & Media
Find recent and archived news, press releases, and stories here.
Feb 15, 2022
Neurocentria obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults with ADHD
Jul 30, 2018
Neurocentria launches phase 2 trial in stage 2 AD patients focusing on cognition, mood, and sleep (NC010)
Apr 6, 2018
Neurocentria Launches Phase 2b Clinical Trial Testing the Efficacy of MMFS in Stage 3 and 4 Alzheimer’s Disease Patients (NC007b)
Mar 3, 2018
Neurocentria Announces Completion and Positive Top-Line Results of MMFS Trial in Adult ADHD
Jul 13, 2017
Neurocentria to Present New Data on MMFS in Mild-Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2017
Oct 28, 2015
Neurocentria Publishes Article Demonstrating its Candidate Compound MMFS can Improve Brain Age by 9 Years in Older Adults with Mild Cognitive Impairment
Jul 13, 2015
Neurocentria Presents Results of Phase 2 Clinical Study of MMFS in Elderly with Mild Cognitive Impairment at Alzheimer’s Association International Conference (AAIC) 2015
Sep 13, 2014
Neurocentria Demonstrates that Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice